ATLANTA--(BUSINESS WIRE)--Sciele Pharma, Inc. (NASDAQ:SCRX): Sciele Pharma, Inc., a specialty pharmaceutical company, today announced revenues and earnings for the second quarter and six months ended June 30, 2008. Pro forma net revenues, a non-GAAP measure, for the second quarter of 2008 increased 17% to $111.3 million, excluding $8.1 million in charges for Sular returns related to the new Sular conversion, from $95.4 million in the second quarter of 2007. Pro forma diluted net income per share, a non-GAAP measure, for the second quarter of 2008 was $0.46, excluding $0.11 in charges for Sular returns and validations, Twinject acquired inventory, and the gain on the disposal of Zebutal, compared with $0.38, excluding $0.09 in non-cash expense related to redemption of contingent convertible notes, for the second quarter of 2007. Earnings before interest, taxes, depreciation and amortization, and stock compensation expense (EBITDAS, a non-GAAP measure) were $25.3 million (including the $8.1 million charge for Sular returns and $2.1 million for Sular validations and Twinject acquired inventory) in the second quarter of 2008 compared with $28.1 million in the second quarter of 2007. Cash flow per share, also a non-GAAP measure, was $0.60 for the second quarter of 2008 compared with $0.53 for the second quarter of 2007.
